chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: TTOX
Symptoms: Fall, Myalgia, Periarthritis
Clinical narrative: had muscle pain; shoulder to freeze; Initial information received on 15-Jun-2023 regarding an unsolicited valid non-serious case received from a consumer.  This case is linked to case 2023SA184688.  This case involves Adult female patient who had muscle pain and shoulder to freeze after receiving vaccine tetanus toxoid.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. At the time of the event, the patient had ongoing Food allergy (allergy to eggs and pork).  On an unknown date in 2015, the patient received an unknown dose of suspect tetanus toxoid produced by unknown manufacturer (formulation, batch number, expiry date unknown) via unknown route in unknown administration site for prophylactic vaccination (immunization). Information on the batch number was requested.  On an unknown date the patient had muscle pain (myalgia) and shoulder to freeze (periarthritis) (unknown latency) following the administration of tetanus toxoid.  It was reported, Caller stated that she has an allergy to eggs and pork, but needs to get her tetanus shot due to an injury to her finger. Caller mentioned that eight years ago, she received a tetanus shot and it never really healed and she had muscle pain causing her shoulder to freeze within a year. Caller reported that she then fell off of her bike and broke the freeze of her shoulder. Caller stated that they found out that the tetanus shot she received contained eggs. Provided Product Composition information, but caller stated that she is trying to find out if there are eggs in the culture because the doctor was only able to tell her it was cultured in a solution.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events (had muscle pain, shoulder to freeze).  At time of reporting, the outcome was Unknown for the event had muscle pain and was Recovered / Resolved on an unknown date for the event shoulder to freeze.
Sex: F
Vaccine: FLU4
Symptoms: Exposure during pregnancy, No adverse event
Clinical narrative: patient is pregnant with no reported adverse event; Initial information received on 06-Sep-2022 regarding an unsolicited valid  non-serious case received from a consumer/non-hcp.  This case involves an unknown age female patient who was exposed to vaccine Influenza quadrival A-B vaccine [Fluzone QIV] in context of patient is pregnant with no reported adverse event. Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported patient is pregnant with no reported adverse event occurred at unknown gestation period.  The date of last menstrual period was not reported. The estimated due date was not reported. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies.   On an unknown date, the patient received a dose of suspect Influenza quadrival A-B vaccine, suspension for injection (dose, strength,lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date the pregnant patient was exposed to  vaccine with no reported adverse event (exposure during pregnancy) (unknown latency)  Relevant prenatal testing after exposure was not reported.  Action taken : not applicable.  At time of reporting, the outcome was Unknown for the event patient is pregnant with no reported adverse event.  Additionally, at time of reporting, the outcome of the pregnancy is unknown.
Age: 0.58
Sex: U
Vaccine: HIBV
Symptoms: No adverse event, Product preparation issue
Clinical narrative: lyophilized vaccine was reconstituted with sterile water, instead of its accompanying saline diluent with no reported adverse event; Initial information received on 21-Jun-2023 regarding an unsolicited valid non-serious case received from other health professional.  This case involves a 7 months old and unknown gender patient for whom lyophilized HIB (PRP/T) vaccine [ACT-HIB] was reconstituted with sterile water, instead of its accompanying saline diluent with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 20-Jun-2023, the patient received 0.5 mL dose of suspect HIB (PRP/T) vaccine, powder and solvent for solution for injection (batch number, expiry date unknown) via intramuscular route in unknown administration site for immunization lyophilized vaccine was reconstituted with sterile water, instead of its accompanying saline diluent with no reported adverse event (product preparation error) (same day latency).  Information on the batch number was requested.  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event lyophilized vaccine was reconstituted with sterile water, instead of its accompanying saline diluent with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 1.5
Sex: U
Vaccine: DTAP
Symptoms: Expired product administered, No adverse event
Clinical narrative: dose of Daptacel expired on 21-Jun-2023 was administered to a patient with no reported adverse event; Initial information was received on 22-Jun-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves 18 months old unknown gender patient to whom an dose of diphtheria-15/tetanus/5 AC pertussis vaccine [Daptacel] expired on 21-jun-2023 was administered with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 22-Jun-2023, the patient received an unknown dose of suspect diphtheria-15/tetanus/5 AC pertussis vaccine (Suspension for injection) (lot:C5893AA, expiry date: 21-Jun-2023, unknown strength) via unknown route in unknown administration site for prophylactic vaccination (Immunization).  On 22-Jun-2023 the patient had an expired dose of daptacel with no reported adverse event (expired product administered) (Latency:same day).  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 1.0
Sex: M
Vaccine: DTAP
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: administered an expired Daptacel to a patient,with no reported adverse event; Initial information received on 22-Jun-2023 regarding an unsolicited valid non-serious case received from other health professional.  This case involves a 1 years old male patient who was administered an expired Diphtheria-15/Tetanus/5 AC Pertussis vaccine [Daptacel] with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received an expired unknown dose of suspect Diphtheria-15/Tetanus/5 AC Pertussis vaccine Suspension for injection of lot C5893AA and expiry: 21-Jun-2023 via unknown route in unknown administration site as prophylactic vaccination (immunization), with no reported adverse event (expired product administered) (latency: same day).  No lab data was reported.  Action taken was not applicable.  At time of reporting, the outcome was Unknown for the event administered an expired daptacel to a patient,with no reported adverse event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 6.0
Sex: F
Vaccine: TDAP
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: 6 year old patient inadvertently received a dose of ADACEL, with no reported adverse event; Initial information received on 23-Jun-2023 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 6 years old female patient who inadvertently received a dose of diphtheria-2/tetanus/5 AC pertussis vaccine [Adacel], with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 25-May-2023, the patient received an unknown dose once of suspect diphtheria-2/tetanus/5 AC pertussis vaccine (Suspension for injection) (lot: U7665BA; expiry date: 04-Mar-2025; strength: standard) via intramuscular route in the left deltoid for Immunization.  On 25-May-2023 the patient inadvertently received a dose of adacel, with no reported adverse event (product administered to patient of inappropriate age) (latency: same day).  Action taken was not applicable.  At time of reporting, the outcome was Unknown for the event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: HIBV
Symptoms: No adverse event, Product preparation error
Clinical narrative: 2 patients received ACT-HIB vaccine that was mixed incorrectly with a different diluent percentage (0.9% sodium chloride) with no reported adverse event; Initial information received on 23-Jun-2023 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves unknown age and unknown gender patient's and reporter reported 2 patients received Hib (Prp/T) Vaccine [Act-Hib] vaccine that was mixed incorrectly with a different diluent percentage (0.9% sodium chloride) with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient's received an unknown dose of suspect HIB (PRP/T) VACCINE Powder and solvent for solution for injection (lot number: UJ797AA/ /UJ801AA; Expiry date: 09-Oct-2023) via unknown route in unknown administration site for immunization.  On an unknown date, the reporter reported 2 patients received Hib (Prp/T) vaccine that was mixed incorrectly with a different diluent percentage (0.9% sodium chloride) with no reported adverse event (product preparation error) (latency: same day).  It was reported, nurse who asked if 0.9% NaCl diluent can be used to mix ActHIB. She has already reported two patients who received ActHIB mixed with 0.9% sodium chloride to VAERS. Additional Description of event Adverse events :Nurse reported 0.9% NaCl diluent was used to mix ActHIB. She has already reported two patients who received ActHIB mixed with 0.9% sodium chloride diluent to VAERS.  Action taken: not applicable.  Outcome: Unknown   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 1.0
Sex: F
Vaccine: DTAP
Symptoms: Expired product administered, No adverse event
Clinical narrative: administered an expired dose of daptacel to one of their patient with no reported adverse event; Initial information was received on 23-Jun-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves 1 years old female patient who was administered an expired dose of diphtheria-15/tetanus/5 AC pertussis vaccine [Daptacel] with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 23-Jun-2023, the patient received a 0.5 ml, once dose of suspect diphtheria-15/tetanus/5 AC pertussis vaccine (Suspension for injection) (lot number, expiry date: unknown) Strength: standard via unknown route in unknown administration site for Immunization. The information on the batch number will not be available.  On an unknown date the patient was administered an expired dose of daptacel with no reported adverse event (expired product administered) (latency: same day).  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: UNK
Symptoms: Expired product administered, No adverse event
Clinical narrative: Pentacel was administered post expiration date with no reported adverse event; Initial information received on 23-Jun-2023 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a patient (unknown age and unknown gender) to whom diphtheria/tetanus/5 hybrid AC pertussis/IPV(VERO)/HIB(PRP/T) vaccine [Pentacel (Vero)]  was administered post expiration date with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient was administered unknown dose of suspect  diphtheria/tetanus/5 hybrid AC pertussis/IPV(VERO)/HIB(PRP/T) vaccine, suspension for injection, (lot UJ666AA; Expiration Date: 04-May-2023, Strength: not reported)  via unknown route in unknown administration site for prophylactic vaccination post expiration date with no reported adverse event (expired product administered) (latency; same day). It was asked what is the grace period for inadvertently administering an expired vaccine; As well as, what would be the following steps regarding this unforeseen issue.  Action taken : not applicable.  Outcome :  Unknown for the event pentacel was administered post expiration date with no reported adverse event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 2.0
Sex: M
Vaccine: TDAP
Symptoms: No adverse event, Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Adacel was inadvertently administered to a 2-year old patient with no reported adverse event; physician ordered a hepatitis A vaccine for the patient, but the medical assistant grabbed the wrong vaccine (ADACEL) and administered it to the patient with no reported adverse event; Initial information received on 23-Jun-2023 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves  2 years old male patient and Diphtheria-2/Tetanus/5 Ac Pertussis Vaccine [Adacel] was inadvertently administered to patient and physician ordered a hepatitis a vaccine for the patient, but the medical assistant grabbed the wrong vaccine (adacel) and administered it to the patient with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 23-Jun-2023, the patient received 0.5 ml Total (1X) dose of suspect Diphtheria-2/Tetanus/5 Ac Pertussis Vaccine Suspension for injection (Strength: Standard; Frequency-once) (with an unknown expiry date, lot number) via intramuscular route in the thigh not otherwise specified (NOS) for immunization. Information on the batch number was requested  On 23-Jun-2023, the patient developed events of Diphtheria-2/Tetanus/5 Ac Pertussis Vaccine was inadvertently administered to a 2-year old patient and physician ordered a hepatitis a vaccine for the patient, but the medical assistant grabbed the wrong vaccine (adacel) and administered it to the patient with no reported adverse event (wrong product administered) (product administered to patient of inappropriate age) (Latency: same day).  It was reported, This situation is reported as a medication error due to ADACEL was inadvertently administered to a 2-year old. This is reported as a medication error due to a 2-year old male patient was inadvertently given ADACEL; the office manager reports that the physician ordered a hepatitis A vaccine for the patient, but the medical assistant grabbed the wrong vaccine (ADACEL) and administered it to the patient.  Action taken: not applicable.  Outcome: Unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 27.0
Sex: M
Vaccine: TDAP
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: expired vaccine given to a patient, with no reported adverse event; Initial information received on 23-Jun-2023 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 27 years old male patient who used expired Diphtheria-2/Tetanus/5 Ac Pertussis Vaccine [Adacel] vaccine, with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a  dose of suspect Diphtheria-2/Tetanus/5 Ac Pertussis Vaccine, Suspension for injection (lot U6900AA, Expiry date: 18-Nov-2022) via unknown route in unknown administration site for prophylactic vaccination (immunization).  On an unknown date the patient used expired Diphtheria-2/Tetanus/5 Ac Pertussis vaccine, with no reported adverse event (expired product administered) (latency: same day).  It was reported, "Nurse called to inquire if there is an extension of expiration date for vaccines. She also wanted to know if an expired vaccine given to a patient is valid and if not when this should repeated. Nurse does not want to provide email address at the time of call. Please see transfer screen for details. Product used : Used."  Action taken with Diphtheria, Tetanus and Acellular Pertussis Vaccine was not applicable.  At time of reporting, the outcome was Unknown for the event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: M
Vaccine: VARZOS
Symptoms: Inappropriate schedule of product administration
Clinical narrative: late dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (on 2019 received 1st dose.).   In MAR-2023, the patient received the 2nd dose of Shingrix. In MAR-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: late dose). The outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK Receipt date: 23-JUN-2023 A reporter reported about him self he received his first dose of Shingrix in 2019 and received his second dose 3 months ago. Consent not asked The patient received 2nd dose of Shingrix later than the recommended interval, which led to lengthening of the vaccine schedule.
Age: 10.0
Sex: M
Vaccine: YF
Symptoms: No adverse event, Product administration error
Clinical narrative: vaccine was given to  patient on hydroxyurea. no adverse reaction reported.
Age: 29.0
Sex: M
Vaccine: HEP
Symptoms: Nausea, Vomiting
Clinical narrative: On June 26, 2023, donor presented for donation and disclosed that he went to the hospital 2 days after receiving a hepatitis B vaccine from out facility. The donor received his 2nd hepatitis B vaccine on 06/16/23 and reported he went to the hospital with nausea and vomiting on 06/18/23. Donor reported no treatment or medication was given or prescribed and he was just monitored and released. Donor stated the nausea and vomiting lasted 4 days untreated. Donor stated he has been stable since 06/22/23.
Age: 74.0
Sex: F
Vaccine: VARZOS
Symptoms: Asthenia, Blood test, Confusional state, Fatigue
Clinical narrative: confusion, weakness, fatigue
Age: 12.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event
Clinical narrative: No adverse events occured. pt showed no signs or symptoms.
Age: 51.0
Sex: F
Vaccine: COVID19-2
Symptoms: Cerebrovascular accident
Clinical narrative: ACUTE STROKE, UNSPECIFIED TYPE AND ARTERY
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Alopecia, Arthralgia, Fatigue, Myalgia, Pain in extremity
Clinical narrative: I had soreness in my arm after receiving the vaccine for about a day.  I have trouble with fatigue with muscle and joint soreness.  I try to rest as much as I can and need to help with the symptoms. For a short time, I had hair loss but that has stopped. If I start with a good day and overdo it my symptoms are worse.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: OBSTRUCTIVE SLEEP APNEA
Age: 88.0
Sex: F
Vaccine: COVID19-2
Symptoms: Hypoxia
Clinical narrative: HYPOXIA
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Pulmonary embolism, Pulmonary infarction
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE PULMONARY EMBOLISM W INFARCTION, UNSPECIFIED
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pruritus, Injection site swelling
Clinical narrative: red, itchy, slightly swollen quarter sized area at injection site
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, Chest discomfort, Chronic obstructive pulmonary disease, Condition aggravated
Clinical narrative: Patient arrives with chief complaint of shortness of breath and a cough.  Patient has history of COPD.  Patient has noted confusion as he arrives with his pants on backwards.  Patient has had tachycardia as well as a low O2 sat at 84% today patient is here with his significant other who says that he has not been having any fevers.  Patient reports very minimal chest discomfort.  Patient has no history of CHF. Associated Symptoms: cough, shortness of breath
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Confusional state, Cough, Dyspnoea, Oxygen saturation decreased, SARS-CoV-2 test positive
Clinical narrative: Patient arrives with chief complaint of shortness of breath and a cough.  Patient has history of COPD.  Patient has noted confusion as he arrives with his pants on backwards.  Patient has had tachycardia as well as a low O2 sat at 84% today patient is here with his significant other who says that he has not been having any fevers.  Patient reports very minimal chest discomfort.  Patient has no history of CHF. Associated Symptoms: cough, shortness of breath
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Tachycardia
Clinical narrative: Patient arrives with chief complaint of shortness of breath and a cough.  Patient has history of COPD.  Patient has noted confusion as he arrives with his pants on backwards.  Patient has had tachycardia as well as a low O2 sat at 84% today patient is here with his significant other who says that he has not been having any fevers.  Patient reports very minimal chest discomfort.  Patient has no history of CHF. Associated Symptoms: cough, shortness of breath
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Feeling abnormal, Impaired work ability, Injection site erythema, Injection site reaction
Clinical narrative: On my fourth vaccine I had  a very red reaction at the site, my arm was very sore and I felt bad enough the next day that I did not go to work. I did not seek medical care.  On 28SEP2022 I contrtacted the COVID-19 virus and was sick for five days my Doctor prescribed Paxlovid for me on about day two.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Pain in extremity, SARS-CoV-2 test positive
Clinical narrative: On my fourth vaccine I had  a very red reaction at the site, my arm was very sore and I felt bad enough the next day that I did not go to work. I did not seek medical care.  On 28SEP2022 I contrtacted the COVID-19 virus and was sick for five days my Doctor prescribed Paxlovid for me on about day two.
Age: 62.0
Sex: F
Vaccine: COVID19-2
Symptoms: Acute respiratory failure
Clinical narrative: ACUTE HYPOXEMIC RESPIRATORY FAILURE
Age: 82.0
Sex: F
Vaccine: COVID19-2
Symptoms: Hypoxia
Clinical narrative: HYPOXEMIA
Age: 84.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Chronic respiratory failure, Respiratory failure
Clinical narrative: J96.10 CHRONIC RESPIRATORY FAILURE 4/19/2023 ACUTE HYPOXEMIC RESPIRATORY FAILURE J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 1/4/2023 ACUTE HYPOXEMIC RESPIRATORY FAILURE J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 3/23/2023 ACUTE HYPOXEMIC RESPIRATORY FAILURE J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/17/2022 ACUTE HYPOXEMIC RESPIRATORY FAILURE
Age: 9.0
Sex: M
Vaccine: HEP, HEPA, IPV, MMRV, TDAP
Symptoms: Computerised tomogram head, Seizure
Clinical narrative: Patient had seizures.
Age: 80.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR. Provider d/c note does not mention COVID (asymptomatic).
Age: 57.0
Sex: M
Vaccine: COVID19-2
Symptoms: Extra dose administered
Clinical narrative: Patient had already received a bivalent covid dose on 12/01/2022, so he received an extra one.
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Bacterial disease carrier, Haematuria, Hypoxia, Lethargy
Clinical narrative: J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 LETHARGY R09.02 HYPOXIA 4/25/2023 LETHARGY J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 MRSA CARRIER R09.02 HYPOXIA 4/25/2023 MRSA CARRIER J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 HEMATURIA R09.02 HYPOXIA 4/25/2023 HEMATURIA J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 PNEUMONIA R09.02 HYPOXIA 4/25/2023 PNEUMONIA J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 UTI (URINARY TRACT INFECTION) R09.02 HYPOXIA 4/25/2023 UTI (URINARY TRACT INFECTION) J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 HYPOXIA R09.02 HYPOXIA 4/25/2023 HYPOXIA
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Pneumonia, Urinary tract infection
Clinical narrative: J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 LETHARGY R09.02 HYPOXIA 4/25/2023 LETHARGY J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 MRSA CARRIER R09.02 HYPOXIA 4/25/2023 MRSA CARRIER J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 HEMATURIA R09.02 HYPOXIA 4/25/2023 HEMATURIA J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 PNEUMONIA R09.02 HYPOXIA 4/25/2023 PNEUMONIA J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 UTI (URINARY TRACT INFECTION) R09.02 HYPOXIA 4/25/2023 UTI (URINARY TRACT INFECTION) J96.00 ACUTE RESPIRATORY FAILURE 4/25/2023 HYPOXIA R09.02 HYPOXIA 4/25/2023 HYPOXIA
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Cardiac failure congestive, Condition aggravated, Hypoxia
Clinical narrative: J96.00 ACUTE RESPIRATORY FAILURE 1/10/2023 CHF EXACERBATION, UNSPECIFIED J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/28/2022 CHF EXACERBATION, UNSPECIFIED R09.02 HYPOXIA 5/1/2023 CHF EXACERBATION, UNSPECIFIED
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Cardiac telemetry normal, Chest X-ray normal, Chronic obstructive pulmonary disease, Condition aggravated
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR. Provider d/c note: "Patient is a 68YO female with past medical history of COPD, HTN, DM2 who presented to the hospital from AFC on 6/25/23 with worsening cough, shortness of breath, and wheezing for few days prior to admission. Patient required frequent use of her rescue inhaler which made her concerned. Patient reports multiple individuals at AFC were diagnosed with COVID-19. Symptoms upon presentation included productive cough of clear-yellow sputum and shortness of breath. She denied fever, chills, weakness, abdominal pain, N/V/D/C. Patient received DuoNebs and Solu-medrol prior to arrival in the ED by EMS. ED work-up was remarkable for hypoxia and tachycardia. Labs were notable for leukocytosis with elevated neutrophils, lymphocytes. RVP was positive for COVID-19. Patient was placed on BiPAP due to respiratory status and eventually weaned off prior to admission. Patient was admitted for presumed COPD exacerbation in the setting of COVID-19.    Patient's hospitalization was unremarkable, she was initially started on Azithromycin and Rocephin for presumed underlying superimposed bacterial pneumonia. Chest XR findings were unremarkable so Rocephin was discontinued prior to discharge. Patient completed a 3-day course of Azithromycin for COPD exacerbation. Patient was also weaned down on oxygen to 0.5-1L to maintain SpO2 88-94%. Patient was on telemetry for hx of paroxysmal Afib with normal rate. Given that patient uses 2L NC SpO2 at baseline, she did not require a walk test prior to discharge. However, patient was encouraged to decrease her home O2 to none at rest and 0.5-1L with exertion.  The patient's leukocyte count remained elevated, presumed reactive from her current infection and COPD exacerbation; however, it was recommended that patient repeat a CBC in 1 month, and if abnormal, follow-up with Hematology. Patient was discharged back to AFC (Home) in stable condition with recommendations to continue Prednisone for 2 additional days"
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dyspnoea, Full blood count, Hypoxia, Infection, Laboratory test abnormal
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR. Provider d/c note: "Patient is a 68YO female with past medical history of COPD, HTN, DM2 who presented to the hospital from AFC on 6/25/23 with worsening cough, shortness of breath, and wheezing for few days prior to admission. Patient required frequent use of her rescue inhaler which made her concerned. Patient reports multiple individuals at AFC were diagnosed with COVID-19. Symptoms upon presentation included productive cough of clear-yellow sputum and shortness of breath. She denied fever, chills, weakness, abdominal pain, N/V/D/C. Patient received DuoNebs and Solu-medrol prior to arrival in the ED by EMS. ED work-up was remarkable for hypoxia and tachycardia. Labs were notable for leukocytosis with elevated neutrophils, lymphocytes. RVP was positive for COVID-19. Patient was placed on BiPAP due to respiratory status and eventually weaned off prior to admission. Patient was admitted for presumed COPD exacerbation in the setting of COVID-19.    Patient's hospitalization was unremarkable, she was initially started on Azithromycin and Rocephin for presumed underlying superimposed bacterial pneumonia. Chest XR findings were unremarkable so Rocephin was discontinued prior to discharge. Patient completed a 3-day course of Azithromycin for COPD exacerbation. Patient was also weaned down on oxygen to 0.5-1L to maintain SpO2 88-94%. Patient was on telemetry for hx of paroxysmal Afib with normal rate. Given that patient uses 2L NC SpO2 at baseline, she did not require a walk test prior to discharge. However, patient was encouraged to decrease her home O2 to none at rest and 0.5-1L with exertion.  The patient's leukocyte count remained elevated, presumed reactive from her current infection and COPD exacerbation; however, it was recommended that patient repeat a CBC in 1 month, and if abnormal, follow-up with Hematology. Patient was discharged back to AFC (Home) in stable condition with recommendations to continue Prednisone for 2 additional days"
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Leukocytosis, Lymphocyte count increased, Neutrophil count increased, Pneumonia bacterial, Positive airway pressure therapy
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR. Provider d/c note: "Patient is a 68YO female with past medical history of COPD, HTN, DM2 who presented to the hospital from AFC on 6/25/23 with worsening cough, shortness of breath, and wheezing for few days prior to admission. Patient required frequent use of her rescue inhaler which made her concerned. Patient reports multiple individuals at AFC were diagnosed with COVID-19. Symptoms upon presentation included productive cough of clear-yellow sputum and shortness of breath. She denied fever, chills, weakness, abdominal pain, N/V/D/C. Patient received DuoNebs and Solu-medrol prior to arrival in the ED by EMS. ED work-up was remarkable for hypoxia and tachycardia. Labs were notable for leukocytosis with elevated neutrophils, lymphocytes. RVP was positive for COVID-19. Patient was placed on BiPAP due to respiratory status and eventually weaned off prior to admission. Patient was admitted for presumed COPD exacerbation in the setting of COVID-19.    Patient's hospitalization was unremarkable, she was initially started on Azithromycin and Rocephin for presumed underlying superimposed bacterial pneumonia. Chest XR findings were unremarkable so Rocephin was discontinued prior to discharge. Patient completed a 3-day course of Azithromycin for COPD exacerbation. Patient was also weaned down on oxygen to 0.5-1L to maintain SpO2 88-94%. Patient was on telemetry for hx of paroxysmal Afib with normal rate. Given that patient uses 2L NC SpO2 at baseline, she did not require a walk test prior to discharge. However, patient was encouraged to decrease her home O2 to none at rest and 0.5-1L with exertion.  The patient's leukocyte count remained elevated, presumed reactive from her current infection and COPD exacerbation; however, it was recommended that patient repeat a CBC in 1 month, and if abnormal, follow-up with Hematology. Patient was discharged back to AFC (Home) in stable condition with recommendations to continue Prednisone for 2 additional days"
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Productive cough, Respiratory disorder, Respiratory viral panel, SARS-CoV-2 test positive, Sputum discoloured
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR. Provider d/c note: "Patient is a 68YO female with past medical history of COPD, HTN, DM2 who presented to the hospital from AFC on 6/25/23 with worsening cough, shortness of breath, and wheezing for few days prior to admission. Patient required frequent use of her rescue inhaler which made her concerned. Patient reports multiple individuals at AFC were diagnosed with COVID-19. Symptoms upon presentation included productive cough of clear-yellow sputum and shortness of breath. She denied fever, chills, weakness, abdominal pain, N/V/D/C. Patient received DuoNebs and Solu-medrol prior to arrival in the ED by EMS. ED work-up was remarkable for hypoxia and tachycardia. Labs were notable for leukocytosis with elevated neutrophils, lymphocytes. RVP was positive for COVID-19. Patient was placed on BiPAP due to respiratory status and eventually weaned off prior to admission. Patient was admitted for presumed COPD exacerbation in the setting of COVID-19.    Patient's hospitalization was unremarkable, she was initially started on Azithromycin and Rocephin for presumed underlying superimposed bacterial pneumonia. Chest XR findings were unremarkable so Rocephin was discontinued prior to discharge. Patient completed a 3-day course of Azithromycin for COPD exacerbation. Patient was also weaned down on oxygen to 0.5-1L to maintain SpO2 88-94%. Patient was on telemetry for hx of paroxysmal Afib with normal rate. Given that patient uses 2L NC SpO2 at baseline, she did not require a walk test prior to discharge. However, patient was encouraged to decrease her home O2 to none at rest and 0.5-1L with exertion.  The patient's leukocyte count remained elevated, presumed reactive from her current infection and COPD exacerbation; however, it was recommended that patient repeat a CBC in 1 month, and if abnormal, follow-up with Hematology. Patient was discharged back to AFC (Home) in stable condition with recommendations to continue Prednisone for 2 additional days"
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Superinfection, Tachycardia, Wheezing
Clinical narrative: Patient with history of COVID vaccines who admitted to hospital with COVID detected PCR. Provider d/c note: "Patient is a 68YO female with past medical history of COPD, HTN, DM2 who presented to the hospital from AFC on 6/25/23 with worsening cough, shortness of breath, and wheezing for few days prior to admission. Patient required frequent use of her rescue inhaler which made her concerned. Patient reports multiple individuals at AFC were diagnosed with COVID-19. Symptoms upon presentation included productive cough of clear-yellow sputum and shortness of breath. She denied fever, chills, weakness, abdominal pain, N/V/D/C. Patient received DuoNebs and Solu-medrol prior to arrival in the ED by EMS. ED work-up was remarkable for hypoxia and tachycardia. Labs were notable for leukocytosis with elevated neutrophils, lymphocytes. RVP was positive for COVID-19. Patient was placed on BiPAP due to respiratory status and eventually weaned off prior to admission. Patient was admitted for presumed COPD exacerbation in the setting of COVID-19.    Patient's hospitalization was unremarkable, she was initially started on Azithromycin and Rocephin for presumed underlying superimposed bacterial pneumonia. Chest XR findings were unremarkable so Rocephin was discontinued prior to discharge. Patient completed a 3-day course of Azithromycin for COPD exacerbation. Patient was also weaned down on oxygen to 0.5-1L to maintain SpO2 88-94%. Patient was on telemetry for hx of paroxysmal Afib with normal rate. Given that patient uses 2L NC SpO2 at baseline, she did not require a walk test prior to discharge. However, patient was encouraged to decrease her home O2 to none at rest and 0.5-1L with exertion.  The patient's leukocyte count remained elevated, presumed reactive from her current infection and COPD exacerbation; however, it was recommended that patient repeat a CBC in 1 month, and if abnormal, follow-up with Hematology. Patient was discharged back to AFC (Home) in stable condition with recommendations to continue Prednisone for 2 additional days"
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Condition aggravated, Joint swelling, Nausea, Pain
Clinical narrative: Patient had previous joint and back pain prior to the injection, but 48 hours after the immunization joint pain, body aches, and joint swelling got worse. Began having nausea and vomiting the weekend of 5/13 and was seen by her PCP on 5/16 and felt like she was itching from the inside out.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Pruritus, Vomiting
Clinical narrative: Patient had previous joint and back pain prior to the injection, but 48 hours after the immunization joint pain, body aches, and joint swelling got worse. Began having nausea and vomiting the weekend of 5/13 and was seen by her PCP on 5/16 and felt like she was itching from the inside out.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Cerebral artery occlusion, Cerebrovascular accident, Hyperglycaemia, Pulmonary embolism, Type 2 diabetes mellitus
Clinical narrative: I26.99 ACUTE PULMONARY EMBOLISM 4/12/2023 DM 2 W HYPERGLYCEMIA I63.512 ACUTE STROKE DUE TO OCCLUSION OF LEFT MIDDLE CEREBRAL ARTERY 5/3/2023 DM 2 W HYPERGLYCEMIA I26.99 ACUTE PULMONARY EMBOLISM 4/12/2023 DM 2 W HYPERGLYCEMIA I63.512 ACUTE STROKE DUE TO OCCLUSION OF LEFT MIDDLE CEREBRAL ARTERY 5/3/2023 DM 2 W HYPERGLYCEMIA
Age: 19.0
Sex: F
Vaccine: MENB
Symptoms: Fatigue, Injection site erythema, Injection site nodule, Injection site pruritus, Pain
Clinical narrative: Having arm pain, redness at injection site, knot at injection site, fatigue, achiness, no fever, some itching around the redness.
Age: 19.0
Sex: F
Vaccine: MENB
Symptoms: Pain in extremity
Clinical narrative: Having arm pain, redness at injection site, knot at injection site, fatigue, achiness, no fever, some itching around the redness.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction
Clinical narrative: ACUTE NON ST ELEVATION MI 4/12/2023 NON-ST ELEVATION MYOCARDIAL INFARCTION ACUTE MI 4/19/2023 NON-ST ELEVATION MYOCARDIAL INFARCTION
Age: 71.0
Sex: F
Vaccine: COVID19-2
Symptoms: Acute myocardial infarction, Obstructive sleep apnoea syndrome, Symptom recurrence
Clinical narrative: OBSTRUCTIVE SLEEP APNEA ACUTE NON ST ELEVATION MI 11/14/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 0.5
Sex: M
Vaccine: HEPA
Symptoms: Inappropriate schedule of product administration
Clinical narrative: provider ordered and MA didn't notice it was too soon
Age: 0.5
Sex: F
Vaccine: COVID19-2
Symptoms: Incorrect dose administered, Wrong product administered
Clinical narrative: The wrong bivalent vaccine and dose were given. The patient was contacted by their PCP, instructed to come back in and received the correct bivalent vaccine per CDC guidelines.
Age: 0.5
Sex: F
Vaccine: HEPA
Symptoms: Inappropriate schedule of product administration
Clinical narrative: provider ordered MA didn't notice it was too soon
Age: 0.5
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered, Wrong product administered
Clinical narrative: The wrong bivalent vaccine and dose were given. The patient was contacted by their PCP, instructed to come back in and received the correct bivalent vaccine per CDC guidelines.
Age: 4.0
Sex: M
Vaccine: DTAPIPV, MMR, VARCEL
Symptoms: Swelling face, Urticaria, Vomiting
Clinical narrative: 10 minutes after receiving vaccines, patient's face started swelling and hives on back.  vomiting started.  patient seen in ER, oral steroid and benadryl given.  symptoms improved.
Age: 1.08
Sex: M
Vaccine: HIBV, HIBV
Symptoms: Expired product administered
Clinical narrative: 6/21/2023 nurse approaches vaccine Coordinator and states, " I gave an expired HIB vaccination to this kid."  Vaccine Coordinator and nurse confirm it was given from the state supply.  Vaccine Coordinator informs nurse  that email will be sent to Community Health Nurse with health department informing of incident. Pts provider informed. 6/22/2023 email submitted.  Pt will be vaccinated a 2nd time with HIB vaccination at 15 month well child check.  Mother called and informed and voiced understanding.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Acute respiratory failure, Asthma, Hypoxia, Wound dehiscence
Clinical narrative: J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/1/2023 OPERATIVE WOUND DEHISCENCE, INIT R09.02 HYPOXIA 3/31/2023 OPERATIVE WOUND DEHISCENCE, INIT J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/1/2023 ABDOMINAL PAIN R09.02 HYPOXIA 3/31/2023 ABDOMINAL PAIN J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/1/2023 PREEXISTING ESSENTIAL HTN IN PREGNANCY, THIRD TRIMESTER R09.02 HYPOXIA 3/31/2023 PREEXISTING ESSENTIAL HTN IN PREGNANCY, THIRD TRIMESTER J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/1/2023 SEVERE PERSISTENT ASTHMA R09.02 HYPOXIA 3/31/2023 SEVERE PERSISTENT ASTHMA
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Blood magnesium normal, Eye disorder, Eye pain, Neurological examination, Pain
Clinical narrative: 12 hrs. after I got the vaccine, I was sleeping, woke up and saw in the mirror I had a spam and it lasted for three weeks, sometimes I saw it and feel it, a week later my right eye, started on the left and then the right eye. A month after the vaccine, I notice itching on my eyebrow and had pain it happens for a few weeks, after a few weeks, two months after, I still had eye pain, On December I saw a Neurologist, gave me an exam, she thought it was not the vaccine, but it was 12 hrs. after the vaccine, and it didn't have the before.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: 12 hrs. after I got the vaccine, I was sleeping, woke up and saw in the mirror I had a spam and it lasted for three weeks, sometimes I saw it and feel it, a week later my right eye, started on the left and then the right eye. A month after the vaccine, I notice itching on my eyebrow and had pain it happens for a few weeks, after a few weeks, two months after, I still had eye pain, On December I saw a Neurologist, gave me an exam, she thought it was not the vaccine, but it was 12 hrs. after the vaccine, and it didn't have the before.
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Transient ischaemic attack
Clinical narrative: TRANSIENT CEREBRAL ISCHEMIA
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Epilepsy, Focal dyscognitive seizures, Status epilepticus, Symptom recurrence
Clinical narrative: EPILEPSY, COMPLEX PARTIAL SEIZURES, INTRACTABLE W STATUS EPILEPTICUS 10/10/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 57.0
Sex: F
Vaccine: HEP
Symptoms: Arthralgia, Joint effusion, Joint swelling, Osteoarthritis, X-ray limb abnormal
Clinical narrative: multiple joint pain, swelling
Age: 1.08
Sex: F
Vaccine: DTAP, VARCEL
Symptoms: Injection site indentation, Lipoatrophy
Clinical narrative: RIGHT LEG WITH INDENTATION IN SKIN SUSPECTED DUE TO VACCINE.  LIPOATROPHY
Age: 69.0
Sex: F
Vaccine: COVID19-2
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: OBSTRUCTIVE SLEEP APNEA